Free tool
FAERS Monitor: Netspot
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208547 or its brand name (Netspot, Gallium Dotatate Ga-68). Reports on generic versions are filed under their own applications.
Reports
190
Serious
20
11% of reports
Hospitalization
6
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea78
- scan gallium abnormal29
- vomiting29
- abdominal pain20
- injection site pain20
- flushing17
- chest pain11
- dizziness9
- erythema8
- hypersensitivity8
- urticaria8
- dyspnoea6
- feeling abnormal6
- hyperhidrosis6
- abdominal discomfort5
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 5 |
| 2018 | 86 |
| 2019 | 20 |
| 2020 | 12 |
| 2021 | 5 |
| 2022 | 12 |
| 2023 | 12 |
| 2024 | 16 |
| 2025 | 17 |
| 2026 | 5 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,969 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| scan gallium abnormalSignal | 29 | 267791.7 | 138746.8 | 2,195,248 |
| flushingSignal | 17 | 18.5 | 11.8 | 266 |
| nauseaSignal | 78 | 10.9 | 9.2 | 719 |
| abdominal painSignal | 20 | 9.5 | 6.3 | 146 |
| injection site painSignal | 20 | 7.2 | 4.8 | 102 |
| vomitingSignal | 29 | 6.8 | 4.9 | 142 |
| chest painSignal | 11 | 6.6 | 3.7 | 47 |
| urticariaSignal | 8 | 5.3 | 2.7 | 24 |
| hyperhidrosisSignal | 6 | 5.2 | 2.3 | 16 |
| hypersensitivitySignal | 8 | 4.8 | 2.4 | 20 |
| erythemaSignal | 8 | 4.3 | 2.2 | 17 |
| abdominal discomfortSignal | 5 | 3.3 | 1.4 | 6 |
| feeling abnormalSignal | 6 | 2.8 | 1.3 | 5 |
| dizziness | 9 | 2.0 | 1.1 | 4 |
| dyspnoea | 6 | 1.2 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.